Cai Yi-Ran, Zhang Hai-Qing, Zhang Zong-DE, Mu Jing, Li Zi-Hui
Department of Pathology, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing Chest Hospital, Beijing 101149, P.R. China.
Oncol Lett. 2011 Mar;2(2):257-264. doi: 10.3892/ol.2010.229. Epub 2010 Dec 23.
Non-small cell lung carcinoma is a leading cause of cancer-related death. Amplification of the two oncogenes MET and SOX2 is frequently encountered in non-small-cell lung carcinoma. This study aimed to use real-time quantitative PCR to assess the correlation of MET and SOX2 amplification with clinicopathological factors. This study was conducted using 115 tissue samples including 57 squamous cell carcinomas (SCCs), 50 adenocarcinomas (ADCs) and 8 adenosquamous carcinomas (ADSCs). A total of 67 patients (58.3%) had a history of smoking. Our results showed that the frequency of MET amplification in SCCs was significantly higher compared to ADCs (χ(2)=8.0, P=0.005). SOX2 showed a markedly preferential amplification in SCCs compared to ADCs in the smoking group cases (P=0.014). Lymph node invasion correlated with MET amplification in SCCs marginally more significantly compared to ADCs (P=0.02). The amplified MET occurred more frequently in SCCs compared to ADCs correlated to tumor dimension at a small scale (<5 cm) (P=0.01). No significant difference in SOX2 amplification was found with regards to lymph node metastasis or tumor dimension. SOX2 and MET amplifications were not associated with gender or age. However, MET amplification in SCCs among patients younger than 64 years of age was higher compared to ADCs and ADSCs (P=0.03). Among ADSCs, MET was not amplified among patients who had never been smokers or were younger than 64 years of age. Neither MET nor SOX2 were amplified in tumors with dimensions <5 cm and without lymph node invasion. Findings of this study showed that MET and SOX2 amplifications are more common in the SCCs of smokers. Moreover, MET amplification is intrinsic in SCCs particularly among smokers, with regards to tumor growth, lymph node invasion and negative correlation to SOX2 amplification. The incidence of discrepancy in the amplifications of MET and SOX2 in SCCs and ADCs suggests that the MET and SOX2 genes play different roles in SCC and ADC tumorigenesis, respectively, particularly among smokers.
非小细胞肺癌是癌症相关死亡的主要原因。在非小细胞肺癌中经常会遇到两种致癌基因MET和SOX2的扩增。本研究旨在使用实时定量PCR评估MET和SOX2扩增与临床病理因素的相关性。本研究使用了115个组织样本，包括57例鳞状细胞癌（SCC）、50例腺癌（ADC）和8例腺鳞癌（ADSC）。共有67例患者（58.3%）有吸烟史。我们的结果显示，与ADC相比，SCC中MET扩增的频率显著更高（χ(2)=8.0，P=0.005）。在吸烟组病例中，与ADC相比，SOX2在SCC中显示出明显更优先的扩增（P=0.014）。与ADC相比，SCC中淋巴结侵犯与MET扩增的相关性略更显著（P=0.02）。与ADC相比，在小尺寸（<5 cm）肿瘤中，SCC中扩增的MET出现频率更高（P=0.01）。在淋巴结转移或肿瘤尺寸方面，未发现SOX2扩增有显著差异。SOX2和MET扩增与性别或年龄无关。然而，64岁以下患者中SCC的MET扩增高于ADC和ADSC（P=0.03）。在ADSC中，从未吸烟或年龄小于64岁的患者中MET未扩增。在尺寸<5 cm且无淋巴结侵犯的肿瘤中，MET和SOX2均未扩增。本研究结果表明，MET和SOX2扩增在吸烟者的SCC中更为常见。此外，就肿瘤生长、淋巴结侵犯以及与SOX2扩增的负相关性而言，MET扩增在SCC中是内在的，尤其是在吸烟者中。SCC和ADC中MET和SOX2扩增差异的发生率表明，MET和SOX2基因分别在SCC和ADC的肿瘤发生中发挥不同作用，尤其是在吸烟者中。
